Many people with chronic kidney diseases develop acquired cystic kidney disease, which is a condition in which the kidney has fluid-filled sacs known as cysts. Acquired cystic kidney disease occurs both, in adults and children. Acquired cystic kidney disease is more likely to develop in patients who are undergoing hemodialysis or peritoneal dialysis. Failure of the kidney causes acquired cystic kidney disease, and not the dialysis. The risk of developing acquired cystic kidney disease usually increases with the number of years an individual is on dialysis. Acquired cystic kidney disease occurs due to chronic renal failure, and the patient does not experience any symptoms. Acquired cystic kidney disease is mainly caused by the waste products which build up in the kidney due to poor filtration. According to the National Institute of Diabetes and Digestive and Kidney Disease, 7 to 22% of people with acquired cystic kidney disease have the disease before dialysis, and almost 60% of people on dialysis for 2 to 4 years develop acquired cystic kidney disease. Around 90% of people on dialysis for 8 years develop acquired cystic kidney disease.
Acquired Cystic Kidney Disease Treatment Market: Drivers and Restraints
The increasing instances of chronic kidney failure which ultimately leads to acquired cystic kidney disease, drives the market for acquired cystic kidney disease treatment, globally. Increasing awareness and development in novel treatments spur the market for acquired cystic kidney disease treatment. Increasing geriatric population and increasing healthcare expenditure drive the market for acquired cystic kidney disease treatment. Increased research and development activities for the treatment of acquired cystic kidney disease by major key players spur the market for acquired cystic kidney disease treatment. Increasing prevalence of diabetes which results in kidney failure boosts the market for acquired cystic kidney disease treatment.
Lack of specific treatment and shortage of skilled physicians and stringent regulations restrain the growth of the acquired cystic kidney disease treatment market.
Acquired Cystic Kidney Disease Treatment Market: Segmentation
Tentatively, the global acquired cystic kidney disease treatment market can be segmented on the basis of treatment type, distribution channel, and geography.
Based on treatment type, the global acquired cystic kidney disease treatment market is segmented as:
- Non-steroidal Anti-inflammatory Medications
Based on distribution channel, the global acquired cystic kidney disease treatment market is segmented as:
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
Acquired Cystic Kidney Disease Treatment Market: Overview
The development of various techniques, increasing number of patients going for dialysis, and favorable reimbursement policies and government initiatives propel the growth of the acquired cystic kidney disease treatment market. On the basis of treatment type, the antibiotics segment accounts for the largest revenue share, owing to increased prescriptions by physicians for the treatment of acquired cystic kidney disease. On the basis of end user, the hospital pharmacies segment accounts for the anticipated growth during the forecast period, owing to the increasing prevalence of chronic kidney diseases and increasing number of dialysis in patients.
Acquired Cystic Kidney Disease Treatment Market: Regional Outlook
Geographically, the global acquired cystic kidney disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific excluding Japan (APEJ), Japan, and the Middle East and Africa (MEA). North America is expected to be the leading market in the global acquired cystic kidney disease treatment market, owing to increasing number of chronic kidney cases and increasing number of surgical procedures for acquired cystic kidney disease. The increasing demand for new techniques for the diagnosis of chronic kidney diseases drives the North American acquired cystic kidney disease treatment market. The acquired cystic kidney disease treatment market in Europe is the second-largest, due to improved infrastructure, increasing awareness of chronic kidney diseases, and increasing healthcare expenditure. The Asia Pacific excluding Japan market is expected to witness fast growth as compared to other regions, due to the large patient population, growing medical tourism, and favorable reimbursement policies. Japan accounts for moderate growth in the acquired cystic kidney disease treatment market, owing to the increasing geriatric population which increasing chronic kidney diseases. Latin America & Middle East & Africa are expected to account for slow growth during the forecast period, owing to slow diagnosis rates and poor healthcare facilities.
Acquired Cystic Kidney Disease Treatment Market: Key Players
The global acquired cystic kidney disease treatment market is highly fragmented, owing to the presence of a large number of manufacturers. Examples of some of the key players operating in the global acquired cystic kidney disease treatment market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Johnson & Johnson Services, Inc. CordenPharma International, Pfizer Limited. Sanofi, Merck & Co., Inc., Allergan, and Baxter International, among others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators, and governing factors, along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers an exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico, Brazil, Argentina, Chile, Peru, and Rest of Latin America)
- Europe [EU -4 (Germany, France, Italy, Spain), BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
- CIS & Russia
- APEJ (Greater China, India, S. Korea, ASEAN Countries and Rest of APEJ)
- Middle East & Africa (GCC Countries, Turkey, Iran, Israel, South Africa, Rest of MEA)
- A detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Benefits of Becoming a Fact.MR Client
- Access to our global market coverage
- Periodic updates on your sector
- Exclusive discounts and offers
- Greater flexibility for customization
- Quick-research assistance for ad-hoc needs
- Access to credible insights Fact.MR analyst interactions
- Access to Fact.MR tools and research to fuel strategy development